The market performance of Nektar Therapeutics has been somewhat stable. Over the past year, the company’s stock achieved a high of $1.93 on 05/13/24, with the lowest value for the same timeframe being $0.41, recorded on 11/13/23.
52-week price history of NKTR Stock
A stock’s 52-week high and low prices can reveal a great deal about its present condition and potential future performance. Nektar Therapeutics’s current trading price is -29.98% away from its 52-week high, while its distance from the 52-week low is 227.19%. The stock’s price range during this period has fluctuated between $0.41 and $1.93. Shares of the company, which operates in the Healthcare sector, recorded a trading volume of around 0.97 million for the day, which was evidently lower than the average daily volume of 1.03 million over the last three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Financial Performance and Market Capitalization
Nektar Therapeutics (NKTR) has experienced a quarterly decline of -2.17% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 248.51M and boasts a workforce of 137 employees.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.2745, with a change in price of -0.0600. Similarly, Nektar Therapeutics recorded 1,437,399 in trading volume during the last 100 days, posting a change of -4.26%.
NKTR Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for NKTR stands at 2.76. Similarly, the long-term debt-to-equity ratio is also 2.49.
NKTR Stock Stochastic Average
The raw stochastic average for Nektar Therapeutics over the last 50 days is presently at 65.85%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 61.11%. Further, the company’s Stochastic %K and %D values for the last 20 days were 75.63% and 78.43%, respectively.
NKTR Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The metric has seen a significant gain of 138.94% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 2.27%. Over the past 30 days, the price of NKTR has fallen by 16.38%. And in the last five days, it has fallen by -6.90%.
